Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform
Key facts
- Who runs it
- Margaret Ragni
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 3
- Started
- Aug 2020
- Expected to end
- Jul 2027
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Eloctate Prophylaxis
- Emicizumab Prophylaxis
- Eloctate ITI plus Emicizumab
- Eloctate ITI
- Record updated
- 20 August 2019
- Why it stopped
- The trial was revised to be two protocols, one Prevention, one Eradication Trials.
Who can take part
- Age
- 4 months to 99 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (29)Hide the full registry criteria
Other criteria
- Prevention Trial, Inclusion Criteria:
- Male children >/= 4 months of age
- Severe hemophilia A (FVIII < 0.01 U/ml)
- No previous bleed or surgery requiring treatment (except circumcision)
- No previous factor VIII product (except for circumcision)
- Willingness to comply with weekly prophylaxis for 48 weeks
- Willingness of parent/caregiver to keep a personal diary of bleeding frequency and factor treatment
- Willingness to make monthly visits and coagulation testing at weeks 4, 12, 24, 36, and 48 (end of study); Prevention Trial, Exclusion Criteria:
- Acquired hemophilia
- Any bleeding disorder other than hemophilia A
- Treatment with clotting factor previously, other than circumcision
- Presence of an inhibitor to factor VIII
- Use of an experimental drug(s)
- Surgery anticipated in the next 48 weeks
- Life expectancy less than 5 years
- Inability to comply with study requirements; Eradication Trial, Inclusion Criteria:
- Male adults or children with no age limitation
- Severe hemophilia A (FVIII <0.01 U/ml)
- Presence of an inhibitor to FVIII (anti-FVIII > 5.0 B.U.)
- Willingness to comply with study drugs for up to 48 weeks
- Willingness to keep a personal diary of bleed frequency and drug treatment
- Willingness to make monthly visits and coagulation testing at weeks 4, 12, 24, 36, and 48 (end of study); Eradication Trial, Exclusion Criteria:
- Acquired hemophilia
- Any bleeding disorder other than hemophilia A
- Current use of Emicizumab, or if used, > 8 weeks since last treatment
- Use of an experimental drug(s)
- Surgery anticipated in the next 48 weeks
- Life expectancy less than 5 years
- Inability to copy with study requirements
Where in United States
- Hemophilia Center of Western PennsylvaniaPittsburgh, United States
About the trial
What the trial wants to find out
This study will evaluate if Eloctate is superior to Emicizumab in reducing inhibitors in children with severe hemophilia when given before the first bleed (preemptive) and continued weekly to prevent bleeds (prophylaxis); and whether Eloctate immune tolerance induction (ITI) plus emicizumab is superior to Eloctate ITI alone in eradicating inhibitor formation in children and adults with severe hemophilia A.
The 4 groups in the trial
- Eloctate ProphylaxisTreatment being tested
Prevention Trial, Arm A: rFVIIIFc (Eloctate) 65 IU/kg weekly will be administered by intravenous infusion in previously untreated children with severe hemophilia A beginning before the first bleed and continued for up to 48 weeks.
- Emicizumab ProphylaxisTreatment being tested
Prevention Trial, Arm B: Emicizumab 1.5 mg/kg weekly (following 4-wk induction at 3 mg/kg weekly) will be administered by subcutaneous injection in previously untreated children with severe hemophilia A beginning before the first bleed and continued for up to 48 weeks.
- Eloctate ITI plus EmicizumabTreatment being tested
Eradication Trial, Arm A: Eloctate 100 IU/kg every other day will be administered by intravenous infusion as immune tolerance plus Emicizumab 1.5 mg/kg weekly by subcutaneous injection in previously treated children and adults with severe hemophilia A and high-titer inhibitors and continued for up to 48 weeks.
- Eloctate ITI AloneExisting treatment, for comparison
Eradication Trial, Arm B: Eloctate 100 IU/kg every other day will be administered by intravenous infusion as immune tolerance alone in previously treated children and adults with severe hemophilia A and high-titer inhibitors and continued for up to 48 weeks.
Treatment: Eloctate ITI
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase III INHIBIT Platform: Prevention Trial, Eloctate vs Emicizumab to Prevent Inhibitors; Eradication Trial: Eloctate Immune Tolerance (ITI) Plus Emicizumab vs vs Eloctate ITI Alone to Eradicate Inhibitors in Severe Hemophilia A
- Publications
- The effect of emicizumab regimen on haemophilia outcomes.The Lancet. Haematology, 2019
- Record updated
- 20 August 2019